Related Experiment Video
Updated: May 9, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
XRCC1 polymorphisms and differentiated thyroid carcinoma risk: a meta-analysis.
Zhen Hu1, Xueying Hu, Jianxiong Long
1School of Public Health, Guangxi Medical University, 22 Shuangyong Road, Nanning, People's Republic of China.
Gene
|July 23, 2013
Summary
This study found no link between X-ray repair cross-complementing group 1 (XRCC1) gene variations and differentiated thyroid carcinoma risk overall. However, a reduced risk was noted in Caucasian populations for the XRCC1 Arg399Gln polymorphism.
Area of Science:
- Genetics
- Oncology
- Molecular Epidemiology
Background:
- Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer.
- Genetic factors, including polymorphisms in DNA repair genes like XRCC1, may influence DTC susceptibility.
- Previous studies on XRCC1 gene polymorphisms and DTC risk have yielded inconsistent results.
Purpose of the Study:
- To quantitatively assess the association between common XRCC1 gene polymorphisms (Arg399Gln, Arg280His, Arg194Trp) and differentiated thyroid carcinoma risk.
- To provide a more precise estimation of this association through a meta-analysis.
Main Methods:
- A comprehensive literature search was performed across three major databases.
- Meta-analysis was conducted using fixed-effect and random-effect models to calculate Odds Ratios (ORs) and 95% Confidence Intervals (CIs).
- Subgroup analyses were performed based on ethnicity.
Main Results:
- No significant association was found between XRCC1 Arg399Gln, Arg280His, and Arg194Trp polymorphisms and overall differentiated thyroid carcinoma risk.
- A statistically significant decreased risk of DTC was observed among Caucasian individuals with the XRCC1 Arg399Gln polymorphism (e.g., Gln/Gln vs. Arg/Arg: OR=0.77, 95% CI=0.60-0.99).
- No association was observed in the Asian population, and no publication bias was detected.
Conclusions:
- The XRCC1 Arg399Gln polymorphism is not generally associated with differentiated thyroid carcinoma risk.
- A potential protective effect of the XRCC1 Arg399Gln polymorphism against DTC may exist in Caucasian populations.
- Further research is warranted to confirm these findings and explore underlying mechanisms.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...